Fusion Antibodies Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Fusion Antibodies hat ein Gesamteigenkapital von £1.5M und eine Gesamtverschuldung von £0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen £2.1M bzw. £604.0K.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

UK£0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	UK£1.20m
Eigenkapital	UK£1.79m
Gesamtverbindlichkeiten	UK£627.00k
Gesamtvermögen	UK£2.42m

Jüngste Berichte zur Finanzlage

Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation

Aug 31

Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation

Jan 25

We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth

May 09

Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth

Jan 04

Recent updates

Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation

Aug 31

Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation

Jan 25

We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth

May 09

Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%

Mar 17

Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth

Jan 04

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: FABDie kurzfristigen Aktiva des Unternehmens (£1.8M) übersteigen seine kurzfristigen Passiva (£554.0K).

Langfristige Verbindlichkeiten: FABDie kurzfristigen Vermögenswerte des Unternehmens (£1.8M) übersteigen seine langfristigen Verbindlichkeiten (£50.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: FAB ist schuldenfrei.

Schulden abbauen: FAB hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: FAB hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: FAB hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 4.1% pro Jahr abnimmt

Fusion Antibodies Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation

Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation

We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth

Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth

Recent updates

New major risk - Share price stability

Fusion Antibodies plc, Annual General Meeting, Oct 08, 2024

Full year 2024 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Fusion Antibodies plc has completed a Follow-on Equity Offering in the amount of £1.375 million.

First half 2024 earnings released: UK£0.023 loss per share (vs UK£0.043 loss in 1H 2023)

Fusion Antibodies plc to Report First Half, 2024 Results on Dec 04, 2023

Fusion Antibodies plc Provides Revenue Guidance for the Fiscal Year 2024

Fusion Antibodies plc Provides Earnings Guidance for the First Half of Fiscal Year 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: UK£0.10 loss per share (vs UK£0.046 loss in FY 2022)

Fusion Antibodies plc Announces Sonya Ferguson, Non-Executive Director, Will Not Be Seeking Re-Election At the AGM

Fusion Antibodies plc, Annual General Meeting, Oct 27, 2023

Fusion Antibodies plc Appoints Stephen Smyth as Interim Chief Financial Officer of the Company with Immediate Effect

Fusion Antibodies plc Announces an Update on the AI/ML-Ab Service Offering

Fusion Antibodies plc Launches New Commercial Service from Its R&D Programme

First half 2023 earnings released: UK£0.043 loss per share (vs UK£0.023 loss in 1H 2022)

Fusion Antibodies plc to Report First Half, 2023 Results on Dec 05, 2022

Less than half of directors are independent

Fusion Antibodies plc, Annual General Meeting, Sep 23, 2022

Fusion Antibodies plc Announces Director Changes

Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation

Full year 2022 earnings released: UK£0.046 loss per share (vs UK£0.11 loss in FY 2021)

Fusion Antibodies plc Announces Bispecific Designs Patent Application

Fusion Antibodies plc Appoints Adrian Kinkaid as Chief Executive Officer, Effective 15 August 2022

Less than half of directors are independent

Fusion Antibodies plc Announces Director Changes, Effective 1 March 2022

Fusion Antibodies plc Announces Resignation of Richard Jones as CEO

Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: UK£0.11 loss per share (vs UK£0.032 loss in FY 2020)

We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth

Fusion Antibodies plc Provides Unaudited Revenue Guidance for the Year Ended March 31, 2021

Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%

Fusion Antibodies plc Announces Executive Changes

Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth

First half 2021 earnings released: UK£0.019 loss per share

Fusion Antibodies plc to Report First Half, 2021 Results on Nov 20, 2020

Fusion Antibodies plc Announces Update on R&D Programme

New 90-day high: UK£1.83

Earnings released

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen